FAK has not been shown to affect the expression or function of MYCN. For these reasons, it was critical that the effects seen with FAK inhibitors on MYCN-amplified long-term passage neuroblastoma cells hold true in PDXs, as was demonstrated in the current study. This evidence concerns the gene MYCN and neuroblastoma.